国产吉西他滨联合顺铂治疗晚期非小细胞肺癌

Combination of Gemcitabine and Cisplatin for Patients with Advanced Non-small-cell Lung Cancer

目的评价国产吉西他滨(GEM)联合顺铂(DDP)治疗晚期非小细胞肺癌(NSCLC)的近期疗效和不良反应。方法27例晚期非小细胞肺癌患者应用择菲联合顺铂化疗,吉西他滨1000mg/m2第1天、第8天,顺铂20mg/m2第1～4天,21d为1个周期,2～3个周期后评价疗效和不良反应。结果总有效率(CR+PR)为40.7%,不良反应为骨髓抑制和胃肠道反应。结论国产吉西他滨联合顺铂治疗晚期非小细胞肺癌疗效较好,不良反应轻。

Objective To evaluate the curative effect and adverse reactions of combination of gemcitabine and cisplatin for pa- tients with advanced non-small-cell lung cancer （NSCLC）. Methods 27 patients with advance NSCLC were treated with this chemotherapy regimen. 1 000 mg/m2 gemcitabine was given at 1st and 8th day and 20 mg/m2 Cisplatin were given from 1st to 4th days. The chemotherapy was repeated every 21 days on two or three cycles. Results Among these 27 patients, the overall re- sponse rate（ CR ＋ PR） was dO. 7%. The main adverse reactions were myelosuppression, nausea and vomiting. Conclusions Gemcitabine combined with Cisplatin is an effective treatment for patients with advance NSCLC and adverse reactions is accepta- ble.